Skip to main content
Neogen Chemicals Limited logo

Neogen Chemicals Limited — Investor Relations & Filings

Ticker · NEOGEN ISIN · INE136S01016 LEI · 335800PFY9B77Z2GOK22 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2026-02-11 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS NEOGEN

About Neogen Chemicals Limited

https://neogenchem.com/

Neogen Chemicals Limited specializes in the development and large-scale manufacturing of bromine-based and lithium-based specialty chemicals. The product portfolio includes a diverse range of bromine derivatives, lithium salts, Grignard reagents, and advanced intermediates. These products serve critical roles in pharmaceutical, agrochemical, and engineering applications. The company has expanded its operations into the energy storage market, focusing on the production of electrolytes and lithium salts for lithium-ion batteries. With a strong emphasis on research and development, the firm provides custom synthesis and contract manufacturing services to global innovators. Manufacturing capabilities are supported by multi-product facilities designed to meet stringent quality standards for complex chemical processes and high-purity requirements.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 88% confidence The document is the formal stock exchange filing under SEBI LODR Regulations announcing and attaching the company’s unaudited standalone and consolidated financial results for the quarter and nine‐month period ended December 31, 2025, together with the independent auditors’ limited review report and detailed statement of results. It contains full interim period financial statements and analysis, not merely a summary or link, so this is a Quarterly/Interim Report rather than an earnings highlight release or simple announcement. Therefore, it falls under Interim / Quarterly Report (IR). 9M 2026
2026-02-11 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges under SEBI Listing Regulations, specifically Regulation 30 and 51(2), which require timely disclosure of material events. The content details receipt of a penalty order from the Office of the Commissioner of Customs regarding non-fulfillment of export obligations and related penalties. It includes specifics of the penalty amounts and mentions the company's ongoing analysis and potential appeal. There are no financial statements, earnings data, or management discussion of results. The document is an announcement of a regulatory/legal event impacting the company, not a financial report or management report. It fits best under Regulatory Filings (RNS) as it is a compliance disclosure about a legal/regulatory matter without substantive financial data or report content.
2026-02-11 English
Options to purchase securities
Regulatory Filings Classification · 95% confidence The document is an official communication from Neogen Chemicals Limited to stock exchanges regarding the granting and vesting of stock options under the company's Employee Stock Option Scheme 2024. It references compliance with SEBI regulations and provides detailed information about the stock option grants, vesting schedules, exercise prices, and other terms. The document is an announcement of a corporate action related to employee stock options, specifically the granting and vesting of options, which falls under disclosures related to share-based employee benefits. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing about voting, dividends, or mergers. The content aligns with announcements about share-based compensation plans and their updates. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a regulatory announcement about stock option grants and vesting under SEBI regulations, and does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing, which are more about share transactions or capital changes rather than employee stock option scheme disclosures.
2026-02-11 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-02-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation letter dated February 6, 2026, from Neogen Chemicals Limited to stock exchanges about the schedule of an earnings conference call for the quarter and nine months ended December 31, 2025. It references Regulation 30 and 51 of the SEBI Listing Regulations, indicating a regulatory disclosure. The content includes details about the date, time, and dial-in information for the earnings call, and mentions that the call will discuss Q3 FY26 results. There is no actual financial data or detailed financial statements included in the text. The document is essentially an announcement of the upcoming earnings call, not the earnings release itself or the transcript. Therefore, it fits best under the category of Call Transcript (CT) only if it contained the transcript, but since it is only the invitation and schedule notice, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call schedule and not the call transcript or earnings release itself.
2026-02-06 English
Board Meeting — Financial Results/Fund Raising
Capital/Financing Update Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board of Directors meeting scheduled to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025, and to evaluate a proposal for raising funds through various instruments. It references compliance with SEBI Listing Regulations and insider trading regulations. The document is a notification of a board meeting and does not contain actual financial statements or detailed financial analysis. It also mentions the trading window closure period related to the financial results announcement. The document length is 3518 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it announces the intent to consider fundraising proposals and financial results approval, but it is not the financial results report itself nor a regulatory filing or report publication announcement.
2026-02-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.